GT200400218A - Formulaciones de liberacion sostenida. - Google Patents

Formulaciones de liberacion sostenida.

Info

Publication number
GT200400218A
GT200400218A GT200400218A GT200400218A GT200400218A GT 200400218 A GT200400218 A GT 200400218A GT 200400218 A GT200400218 A GT 200400218A GT 200400218 A GT200400218 A GT 200400218A GT 200400218 A GT200400218 A GT 200400218A
Authority
GT
Guatemala
Prior art keywords
sustained release
release formulations
administration
formulations
sustained
Prior art date
Application number
GT200400218A
Other languages
English (en)
Inventor
Erick J Benjamin
Wendy A Dulin
Yanning Lin
Kai Zhuang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34572826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200400218(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200400218A publication Critical patent/GT200400218A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A FORMULACIONES DE DOSIS DE LIBERACION CONTROLADA Y SOSTENIDA DE COMPUESTOS DOPAMINERGICOS, EN PARTICULAR A APLINDORE, ESTAS FORMULACIONES SON UTILES PARA TRATAR ENFERMEDADES TALES COMO LA EZQUIZOFRENIA, ENFERMEDAD DE PARKINSON, SINDROME DE TOURETTE, PSICOSIS, HIPERPROLACTAMIA, ADICCION A DROGAAS Y MANIA AGUDA EN EL DESORDEN BIPOLAR.
GT200400218A 2003-10-29 2004-10-28 Formulaciones de liberacion sostenida. GT200400218A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51531503P 2003-10-29 2003-10-29

Publications (1)

Publication Number Publication Date
GT200400218A true GT200400218A (es) 2005-06-06

Family

ID=34572826

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200400218A GT200400218A (es) 2003-10-29 2004-10-28 Formulaciones de liberacion sostenida.

Country Status (22)

Country Link
US (5) US20050095292A1 (es)
EP (1) EP1675583B1 (es)
JP (1) JP5547865B2 (es)
KR (1) KR101409724B1 (es)
CN (2) CN1874767A (es)
AR (1) AR046222A1 (es)
AU (1) AU2004286855B2 (es)
BR (1) BRPI0415953B8 (es)
CA (1) CA2543045C (es)
ES (1) ES2405404T3 (es)
GT (1) GT200400218A (es)
HK (1) HK1089394A1 (es)
IL (1) IL174958A (es)
MX (1) MXPA06004752A (es)
NO (1) NO20062004L (es)
PA (1) PA8616201A1 (es)
PE (1) PE20050484A1 (es)
RU (1) RU2376988C2 (es)
SG (1) SG147450A1 (es)
TW (1) TW200517106A (es)
WO (1) WO2005044262A1 (es)
ZA (1) ZA200603409B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044262A1 (en) 2003-10-29 2005-05-19 Wyeth Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
US8858993B2 (en) * 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
CA2620108A1 (en) * 2005-08-26 2007-03-01 Bpsi Holdings Llc Drug compositions containing controlled release hypromellose matrices
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
EP2334378B1 (en) 2008-08-19 2014-04-09 XenoPort, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
IL294658A (en) * 2008-12-22 2022-09-01 Novartis Ag Dosage regimen of an s1p receptor agonist
WO2011011060A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
MX357304B (es) 2011-01-07 2018-07-04 Novartis Ag Formulaciones inmunosupresoras.
EP3718546A1 (en) 2011-08-16 2020-10-07 Cardiora Pty Ltd Controlled-release formulation
CA2882713A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
EP2887933A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016101024A1 (en) 2014-12-22 2016-06-30 Baker Idi Heart & Diabetes Institute Holdings Limited Method of treatment
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
CN111511353A (zh) 2017-06-21 2020-08-07 田边三菱制药株式会社 耐胃液的控释口服剂型
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same
JP6983139B2 (ja) * 2017-11-27 2021-12-17 信越化学工業株式会社 固形製剤用組成物並びに固形製剤及びその製造方法
AU2019207625A1 (en) 2018-01-09 2020-07-30 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
US10933020B2 (en) 2018-09-28 2021-03-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
TWI841545B (zh) * 2018-12-12 2024-05-11 日商田邊三菱製藥股份有限公司 耐胃性控制釋放經口劑型
CN115710224A (zh) * 2020-06-28 2023-02-24 海创药业股份有限公司 一种喹啉类化合物晶型及其制备方法
CN116549406B (zh) * 2023-05-23 2023-12-19 北京丰科睿泰医药科技有限公司 一种盐酸曲唑酮缓释片剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
JP2687448B2 (ja) * 1988-06-22 1997-12-08 大正製薬株式会社 イブプロフェン徐放性製剤
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
US4988679A (en) * 1989-01-03 1991-01-29 Leonard Chavkin Liquid sustained release composition
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
JPH05505599A (ja) 1990-03-15 1993-08-19 ジ・アップジョン・カンパニー 治療上有用な複素環インドール化合物類
JP2600978B2 (ja) * 1990-05-25 1997-04-16 日産自動車株式会社 サスペンションのアッパリンク支持部構造
US5128366A (en) * 1990-07-05 1992-07-07 Shinogi & Co., Ltd. Pyrrole derivatives
US5168387A (en) * 1990-12-11 1992-12-01 Central Glass Company, Limited Variable light transmittance device
US5633376A (en) * 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5166367A (en) 1991-06-21 1992-11-24 American Home Products Corporation Antipsychotic benzodioxan derivatives
US5126366A (en) 1991-06-21 1992-06-30 American Home Products Corporation Aminophenoxyalkyl derivatives of benzodioxan
US5189171A (en) 1991-06-21 1993-02-23 American Home Products Corporation Antipsychotic benzodioxan derivatives
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5235055A (en) * 1992-09-02 1993-08-10 American Home Products Corporation Antipsychotic quinoline derivatives of benzodioxanmethylamine
US5245051A (en) * 1992-09-03 1993-09-14 American Home Products Corporation Antipsychotic chroman derivatives of benzodioxanmethylamine
EP0939135A1 (en) 1992-12-21 1999-09-01 Duphar International Research B.V Substantially pure hetero-bicyclic alcohol enantiomers
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
AU1096697A (en) * 1995-12-01 1997-06-27 Janssen Pharmaceutica N.V. Cisapride sustained release
JPH09315969A (ja) * 1996-05-24 1997-12-09 Taiyo Yakuhin Kogyo Kk イブジラスト含有徐放性医薬品組成物及びその製造方法
GB9627005D0 (en) 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents
GB9704948D0 (en) 1997-03-11 1997-04-30 Knoll Ag Therapeutic agents
TW587938B (en) 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
EP1261340B1 (en) * 1999-07-13 2009-05-13 Alpha Research Group, LLC Compositions and methods for the treatment of parkinson's disease
EP1235574B1 (en) * 1999-12-03 2005-02-02 Polichem S.A. Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
IL149669A0 (en) 1999-12-10 2002-11-10 Wyeth Corp NEW THERAPEUTIC COMBINATIONS OF (S) -2-(BENZYLAMINO-METHYL)-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e] INDOL-8-ONE AND NEUROLEPTICS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS
US6350773B1 (en) 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
US6524618B1 (en) * 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
TW200526221A (en) * 2003-09-02 2005-08-16 Imran Ahmed Sustained release dosage forms of ziprasidone
WO2005044262A1 (en) * 2003-10-29 2005-05-19 Wyeth Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
TW200811182A (en) 2006-05-25 2008-03-01 Wyeth Corp Oxindoledioxans, synthesis thereof, and intermediates thereto

Also Published As

Publication number Publication date
NO20062004L (no) 2006-07-07
RU2376988C2 (ru) 2009-12-27
KR20060110281A (ko) 2006-10-24
EP1675583B1 (en) 2013-02-27
KR101409724B1 (ko) 2014-06-19
US20050095292A1 (en) 2005-05-05
US20230061743A1 (en) 2023-03-02
JP5547865B2 (ja) 2014-07-16
PA8616201A1 (es) 2005-05-24
BRPI0415953B8 (pt) 2021-05-25
MXPA06004752A (es) 2006-07-05
US10463648B2 (en) 2019-11-05
CN1874767A (zh) 2006-12-06
US10292966B2 (en) 2019-05-21
HK1089394A1 (en) 2006-12-01
US20180193311A1 (en) 2018-07-12
EP1675583A1 (en) 2006-07-05
RU2006118321A (ru) 2007-12-10
CA2543045A1 (en) 2005-05-19
IL174958A0 (en) 2008-04-13
AR046222A1 (es) 2005-11-30
AU2004286855A1 (en) 2005-05-19
JP2007509970A (ja) 2007-04-19
WO2005044262A1 (en) 2005-05-19
US20200138781A1 (en) 2020-05-07
AU2004286855B2 (en) 2011-04-21
ZA200603409B (en) 2010-10-27
TW200517106A (en) 2005-06-01
BRPI0415953B1 (pt) 2018-12-26
ES2405404T3 (es) 2013-05-31
PE20050484A1 (es) 2005-10-13
CA2543045C (en) 2013-12-17
SG147450A1 (en) 2008-11-28
CN102335116A (zh) 2012-02-01
US11179369B2 (en) 2021-11-23
BRPI0415953A (pt) 2007-01-02
US20180344695A1 (en) 2018-12-06
IL174958A (en) 2012-08-30

Similar Documents

Publication Publication Date Title
GT200400218A (es) Formulaciones de liberacion sostenida.
BR122019027412B8 (pt) composição farmacêutica de liberação sustentada na forma de micropartículas, processo para preparação das ditas micropartículas, e kit de administração
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
MX2007010996A (es) Nuevas composiciones de liposomas.
NI200700078A (es) Capuchón para dispositivos para la administración de fármacos
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
BR112015010663A2 (pt) formas de dosagem de ruxolitinib de liberação sustentada
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
UY29093A1 (es) Derivados de 4-oxo-3. 4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones que los contienen, procesos de preparación y aplicaiones.
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
UY31068A1 (es) Ligandos purinoreceptores p2x, metodos para la prparacion de los mismos, composiciones farmaceuticas que los contienen y sus usos 570
CY1112478T1 (el) Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες
UY31676A1 (es) "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
HN2001000037A (es) Derivados de eteres de pirazol como agentes antiinflamatorios/analgesicos
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
UY31294A1 (es) Derivados de tetrahidrocarbozol, métodos para obtenerlos, formulaciones que los contienen y usos de los mismos
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
UY31346A1 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
GT200500328A (es) Sal l-tartrato de n-1-adamantil-2-{3-[(2r)-2-({(2r)-2-hidroxi-2[4-hidroxi-3-(hidroximetil)fenil]etil}amino)propil]fenil}acetamida.